Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
SPHS's Cash-to-Debt is ranked higher than
97% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. SPHS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SPHS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39  Med: 620.38 Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -4.73
Beneish M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -138.83
SPHS's ROE % is ranked lower than
95% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. SPHS: -138.83 )
Ranked among companies with meaningful ROE % only.
SPHS' s ROE % Range Over the Past 10 Years
Min: -2308.71  Med: -124.66 Max: -63.39
Current: -138.83
-2308.71
-63.39
ROA % -56.08
SPHS's ROA % is ranked lower than
92% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. SPHS: -56.08 )
Ranked among companies with meaningful ROA % only.
SPHS' s ROA % Range Over the Past 10 Years
Min: -157.85  Med: -74.28 Max: -35.16
Current: -56.08
-157.85
-35.16
ROC (Joel Greenblatt) % -196534.48
SPHS's ROC (Joel Greenblatt) % is ranked lower than
99% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. SPHS: -196534.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SPHS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -103542.86  Med: -13108.2 Max: -4570.3
Current: -196534.48
-103542.86
-4570.3
3-Year Revenue Growth Rate -100.00
SPHS's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. SPHS: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SPHS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -25.2
Current: -100
3-Year EBITDA Growth Rate -25.70
SPHS's 3-Year EBITDA Growth Rate is ranked lower than
97% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. SPHS: -25.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SPHS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.4  Med: -7 Max: 72.7
Current: -25.7
-49.4
72.7
3-Year EPS without NRI Growth Rate -29.40
SPHS's 3-Year EPS without NRI Growth Rate is ranked lower than
96% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SPHS: -29.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SPHS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: -5 Max: 70.9
Current: -29.4
-50.5
70.9
GuruFocus has detected 4 Warning Signs with Sophiris Bio Inc $SPHS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SPHS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

SPHS Guru Trades in

SPHS Guru Trades in

Q2 2015

SPHS Guru Trades in Q2 2015

Jim Simons 35,618 sh (New)
» More
Q3 2015

SPHS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SPHS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 3741
Compare:NAS:MEIP, NAS:LPCN, NAS:IMMY, NAS:EPIX, OTCPK:ACNNF, NAS:TYHT, OTCPK:BIOYF, NAS:GALT, NAS:PSDV, NAS:ARLZ, OTCPK:HYYDF, OTCPK:ICCLF, OTCPK:SENZ, OTCPK:MRPHF, OTCPK:OWCP, NAS:AGRX, NAS:ADMP, NAS:JNP, OTCPK:MGWFF, NAS:OREX » details
Traded in other countries:BFF1.Germany,
Headquarter Location:USA
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. The Company is engaged in research and development of products for the treatment of urological diseases. It is currently developing PRX302 for treatment of benign prostatic hyperplasia.

Sophiris Bio Inc was formed in May 2003 under the predecessor to the Business Corporations Act by the amalgamation of Stratos Biotechnologies Inc., Nucleus BioScience Inc. and Brightwave Ventures Inc. It began operations on January 11, 2002. The Company's operations were initially located in Vancouver, British Columbia. Effective April 2, 2012, the Company changed its name from Protox Therapeutics Inc. to Sophiris Bio Inc. The Company is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of urological diseases. It is currently developing PRX302 for treatment of the symptoms of benign prostatic hyperplasia. BPH is a non-cancerous enlargement of the prostate gland that commonly affects men who are age 50 and older. The Company expects that PRX302 will compete with the current treatment options for the symptoms of BPH, which include oral drug therapy and surgery. Its business and operations are subject to a variety of U.S. federal, state and local, and foreign supranational, national, provincial and municipal laws, regulations and trade practices. As of December 31, 2012, it had nine full-time employees and one part-time employee.

Ratios

vs
industry
vs
history
PB Ratio 6.10
SPHS's PB Ratio is ranked lower than
77% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. SPHS: 6.10 )
Ranked among companies with meaningful PB Ratio only.
SPHS' s PB Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.25 Max: 12.08
Current: 6.1
0.18
12.08
Current Ratio 23.77
SPHS's Current Ratio is ranked higher than
96% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. SPHS: 23.77 )
Ranked among companies with meaningful Current Ratio only.
SPHS' s Current Ratio Range Over the Past 10 Years
Min: 0.6  Med: 5.51 Max: 118.33
Current: 23.77
0.6
118.33
Quick Ratio 23.77
SPHS's Quick Ratio is ranked higher than
96% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. SPHS: 23.77 )
Ranked among companies with meaningful Quick Ratio only.
SPHS' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 5.51 Max: 118.33
Current: 23.77
0.6
118.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -23.10
SPHS's 3-Year Average Share Buyback Ratio is ranked lower than
96% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. SPHS: -23.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SPHS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -235.3  Med: -50.8 Max: -23.1
Current: -23.1
-235.3
-23.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.65
SPHS's Price-to-Net-Cash is ranked higher than
67% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. SPHS: 6.65 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SPHS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.77  Med: 7.65 Max: 127.27
Current: 6.65
0.77
127.27
Price-to-Net-Current-Asset-Value 6.15
SPHS's Price-to-Net-Current-Asset-Value is ranked higher than
59% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. SPHS: 6.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SPHS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.62  Med: 7.15 Max: 87.5
Current: 6.15
0.62
87.5
Price-to-Tangible-Book 6.10
SPHS's Price-to-Tangible-Book is ranked lower than
66% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. SPHS: 6.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SPHS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.62  Med: 6.99 Max: 83.67
Current: 6.1
0.62
83.67
Earnings Yield (Greenblatt) % -23.58
SPHS's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. SPHS: -23.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SPHS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 27.3  Med: 49.6 Max: 10436.9
Current: -23.58
27.3
10436.9

More Statistics

EPS (TTM) $ -0.45
Beta2.19
Short Percentage of Float9.89%
52-Week Range $0.90 - 8.55
Shares Outstanding (Mil)30.11
» More Articles for SPHS

Headlines

Articles On GuruFocus.com
Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer May 23 2017 
Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights May 15 2017 
Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Can May 15 2017 
Sophiris Bio to Present at 16th Annual Needham Healthcare Conference Mar 31 2017 
Weekly 3-Year Low Highlights: STRA, IMI, HXM, SPHS Jan 06 2014 
From The Land of What If - Smart Proteins and Debt Collectors Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 

More From Other Websites
Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer May 23 2017
SPHS: Dosing of Patients in Phase 2b Trial of Topsalysin in Prostate Cancer to Initiate Soon May 18 2017
Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights May 15 2017
Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate... May 15 2017
Sophiris Bio to Present at 16th Annual Needham Healthcare Conference Mar 29 2017
SPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway Mar 29 2017
Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate... Mar 27 2017
Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd... Mar 23 2017
Sophiris Bio to Present at 29th Annual ROTH Conference Mar 06 2017
Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference Jan 30 2017
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present... Jan 30 2017
Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Dec 01 2016
Three Biotech Companies With Large Upside Potential Oct 06 2016
Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016 Sep 20 2016
Sophiris Bio (SPHS) Stock Coverage Initiated at Roth Capital Sep 15 2016
SPHS: Initiating on Sophiris Bio, Inc.; Developing Novel Treatments for Urologic Conditions Sep 12 2016
5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside Sep 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)